BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $67.36 -1.71%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.76, $0.02 better than the analyst estimate of $0.74. Revenue for the quarter came in at $766 million versus the consensus estimate of $755.94 million.
GUIDANCE:
BioMarin Pharma sees FY2026 EPS of $4.85-$5.05, versus the consensus of $4.64. BioMarin Pharma sees FY2026 revenue of $3.83-3.93 million, versus the consensus of $3.83 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
- Full Circle Lithium closes $5.14M private placement
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
